Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

Inclusion Criteria: * Age 18 to 65 years (inclusive), male or female. * Documented history of post-surgical chronic HP or autoimmune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is confirmed based on a history of hypocalcemia accompanied by an inappropriately low serum PTH level (below the upper limit of the normal range of the local laboratory). \* Note: If a subject lacks documented diagnosis of chronic HP but has exhibited hypocalcemia accompanied by an inappropriately low serum PTH level for at least 26 weeks prior to screening, and is judged by the investigator to meet the diagnostic criteria for chronic HP, they will be considered eligible for this criterion. * Poorly controlled or intolerant to conventional therapy (calcium and active vitamin D). * Body Mass Index (BMI) of 17 to 40 kg/m² (inclusive) at screening. * If aged ≤ 25 years, radiological evidence of closed epiphyses based on X-ray of the non-dominant hand (wrist and palm). Exclusion Criteria: * Impaired PTH response (pseudohypoparathyroidism), characterized by PTH resistance and elevated PTH levels in the presence of hypocalcemia. * History of allergic predisposition, or known allergy to the investigational drug or polyethylene glycol (PEG)-containing medications. * Any disease other than HP that may affect calcium metabolism, calcium-phosphate homeostasis, or PTH levels, such as: active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly…